Hologic, Inc. (HOLX): Price and Financial Metrics
Hologic, Inc. (HOLX)
Today's Latest Price: $66.38 USD
Updated Oct 20 4:15pm
Add HOLX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
HOLX Stock Summary
- Hologic Inc's market capitalization of $17,354,601,066 is ahead of 89.55% of US-listed equities.
- HOLX's went public 30.59 years ago, making it older than 84.24% of listed US stocks we're tracking.
- Over the past twelve months, HOLX has reported earnings growth of 411.9%, putting it ahead of 96.27% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Hologic Inc are RMD, PKI, GGG, FTV, and VAR.
- Visit HOLX's SEC page to see the company's official filings. To visit the company's web site, go to www.hologic.com.
HOLX Stock Price Chart Interactive Chart >
HOLX Price/Volume Stats
| Current price | $66.38 | 52-week high | $73.63 |
| Prev. close | $67.01 | 52-week low | $26.49 |
| Day low | $66.35 | Volume | 883,700 |
| Day high | $67.78 | Avg. volume | 2,548,482 |
| 50-day MA | $64.69 | Dividend yield | N/A |
| 200-day MA | $54.41 | Market Cap | 17.19B |
Hologic, Inc. (HOLX) Company Bio
Hologic Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States and internationally. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company was founded in 1985 and is based in Bedford, Massachusetts.
HOLX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $66.38 | $24.15 | -64% |
Below please find a table outlining a discounted cash flow forecast for HOLX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Hologic Inc ranked in the 24th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 63.83%. In terms of the factors that were most noteworthy in this DCF analysis for HOLX, they are:
- Hologic Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
- The weighted average cost of capital for the company is 8. This value is greater than only 21.45% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -65% |
| 1% | -64% |
| 2% | -64% |
| 3% | -64% |
| 4% | -63% |
| 5% | -63% |
SNN, WST, CAH, TMO, and VIVO can be thought of as valuation peers to HOLX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...